Cytokinetics, Incorporated (CYTK)

51,94 -0,84 (-1,59%) Börsenschluss: 04:00PM EDT

Cytokinetics, Incorporated

350 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 624 3000
https://www.cytokinetics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 423

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Robert I. Blum	CEO, President & Director	1,33M	9,61M	1964
Mr. Robert C. Wong	VP & Chief Accounting Officer	495,72k	N/A	1968
Dr. Fady Ibraham Malik FACC, M.D., Ph.D.	Executive Vice President of Research & Development	839,66k	586,17k	1964
Mr. Andrew M. Callos	Executive VP & Chief Commercial Officer	752,84k	N/A	1969
Dr. James A. Spudich Ph.D.	Co-Founder & Member of Scientific Advisory Board	21,94k	N/A	1942
Mr. Sung H. Lee	Executive VP & CFO	N/A	N/A	1970
Mr. Jeff Lotz	Vice President of Sales & Operations	N/A	N/A	N/A
Mr. Matt Yang	Vice President of Corporate Finance and Financial Planning & Analysis	N/A	N/A	N/A
Mr. Steven M. Cook	Senior Vice President of Global Supply Chain Operations & Technical Operations	N/A	N/A	1959
Ms. Kari K. Loeser J.D.	VP & Chief Compliance Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Corporate Governance

Cytokinetics, Incorporateds ISS Governance QualityScore, Stand 1. Juni 2024, lautet 5. Die grundlegenden Scores sind Audit: 2, Vorstand: 4, Shareholderrechte: 7, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.